| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Pathology*
and
Anatomy,
Seoul National University College of
Medicine, and Institute of Allergy and Clinical
Immunology,
Seoul, and the Department of
Otolaryngology,§
Inje University College of
Medicine, Kimhae, Korea
Programmed cell death (PCD) is a prominent feature of the
development of the immune and nervous systems. In both systems,
widespread PCD occurs in primitive progenitor cells during development.
In this study, we demonstrated that Ewing's sarcoma (ES)
cells, undifferentiated neural precursors, underwent
apoptosis upon engagement of CD99 with anti-CD99 monoclonal antibody.
Apoptosis via CD99 occurred only in the undifferentiated state of ES
cells, but not in differentiated ES cells. CD99-induced
apoptosis in ES cells appeared to require de novo synthesis
of RNA and protein as well as caspase activation. Cyclosporin
A, known to be a potent inhibitor of both calcineurin
activation and mitochondrial permeability transition pore
opening, inhibited CD99-mediated apoptosis, whereas
FK-506, a specific calcineurin inhibitor, did
not, indicating the induction of CD99-mediated apoptosis
through a calcineurin-independent pathway. Furthermore, the
dying cells displayed the reduction of mitochondrial transmembrane
potential (
m). These results suggest that CD99 engagement induce
CsA-inhibitable mitochondrial permeability transition pore
opening, followed by a reduction of 
m and caspase
activation, thereby leading to apoptosis. Based on these
results, we suggest the possible involvement of CD99 in the
apoptotic processes that occur during nervous system development and
also its application in immunotherapeutic trials for ES
cases.
This article has been cited by other articles:
![]() |
M. C. Manara, G. Bernard, P.-L. Lollini, P. Nanni, M. Zuntini, L. Landuzzi, S. Benini, G. Lattanzi, M. Sciandra, M. Serra, et al. CD99 Acts as an Oncosuppressor in Osteosarcoma Mol. Biol. Cell, April 1, 2006; 17(4): 1910 - 1921. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Leverkus, A. D. McLellan, M. Heldmann, A. O. Eggert, E.-B. Brocker, N. Koch, and E. Kampgen MHC class II-mediated apoptosis in dendritic cells: a role for membrane-associated and mitochondrial signaling pathways Int. Immunol., August 1, 2003; 15(8): 993 - 1006. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cermak, S. Simova, A. Pintzas, V. Horejsi, and L. Andera Molecular Mechanisms Involved in CD43-mediated Apoptosis of TF-1 Cells. ROLES OF TRANSCRIPTION, Daxx EXPRESSION, AND ADHESION MOLECULES J. Biol. Chem., March 1, 2002; 277(10): 7955 - 7961. [Abstract] [Full Text] [PDF] |
||||
![]() |
I.-s. Lee, M. K. Kim, E. Y. Choi, A. Mehl, K. C. Jung, M. C. Gil, M. Rowe, and S. H. Park CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-{kappa}B Blood, June 1, 2001; 97(11): 3596 - 3604. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Pettersen, G. Bernard, M. K. Olafsen, M. Pourtein, and S. O. Lie CD99 Signals Caspase-Independent T Cell Death J. Immunol., April 15, 2001; 166(8): 4931 - 4942. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Sohn, Y. K. Shin, I.-S. Lee, Y. M. Bae, Y. H. Suh, M. K. Kim, T. J. Kim, K. C. Jung, W. S. Park, C.-S. Park, et al. CD99 Regulates the Transport of MHC Class I Molecules from the Golgi Complex to the Cell Surface J. Immunol., January 15, 2001; 166(2): 787 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Landuzzi, C. De Giovanni, G. Nicoletti, I. Rossi, C. Ricci, A. Astolfi, L. Scopece, K. Scotlandi, M. Serra, G. P. Bagnara, et al. The Metastatic Ability of Ewing's Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit Am. J. Pathol., December 1, 2000; 157(6): 2123 - 2131. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Scotlandi, N. Baldini, V. Cerisano, M. C. Manara, S. Benini, M. Serra, P.-L. Lollini, P. Nanni, G. Nicoletti, G. Bernard, et al. CD99 Engagement: An Effective Therapeutic Strategy for Ewing Tumors Cancer Res., September 1, 2000; 60(18): 5134 - 5142. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |